Tetrapyrroles and derivatives
Abcam CL-316243 disodium salt, adrenergic-beta3 receptor agonist, 25MG
MW 465.8 Da, Purity >99%. Selective adrenergic-β3 receptor agonist. Induces adipose tissue remodelling in rat. Hypoglycemic agent. Active *in vivo* and *in vitro*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IBM x , Non-specific cAMP and cGMP inhibitor, 100MG
MW 222.24 Da, Purity >98%. Non-specific cAMP and cGMP inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dorsomorphin (Compound C), AMP-kinase inhibitor, 50MG
MW 399.5 Da, Purity >99%. Potent, selective and reversible inhibitor of AMP-kinase (Ki = 109 nM). Inhibits AMPK activation induced by AICAR (ab120358) and metformin (ab120847). Selective inhibitor of bone morphogenetic protein (BMP) type I receptors (ALK2, ALK3 and ALK6). Does not affect ZAPK, SYK, PKCθ, PKA and JAK3. Cell-permeable. Also available in a water soluble form (Dorsomorphin dihydrochloride - ab144821).
The product is subject to the following: Abcam Restricted Use Statement
Abcam MPEP hydrochloride, mGlu5 antagonist, 50MG
MW 229.7 Da, Purity >99%. Subtype selective and potent non-competitive mGlu₅ antagonist (IC₅₀ = 36 nM). Central effects following systemic administration in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB-277011-A dihydrochloride, D3 antagonist, 25MG
MW 511.5 Da, Purity >98%. Potent, highly selective D3 receptor antagonist (pKi = 7.95 at hD3 receptors). Exhibits over 100-fold selectivity over D2 receptors. Blood-brain barrier (BBB) permeable. Diminishes nicotine, cocaine and alcohol self-administration. Interferes with mechanisms of drug-taking and reinstatement of drug-taking behaviours.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 206553 hydrochloride, 5-HT2B and 5-HT2C receptor antagonist, 10MG
MW 292.33 Da, Purity >99%. Potent and selective 5-HT2B and 5-HT2C serotonin receptor antagonist (pKi values are 7.92 (5-HT2C), 5.78 (5-HT2A), 7.65 (5-HT2B), 1A), 1D), 1E) and 1F). Centrally active following oral administration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Undecylprodigiosin, Apoptotic and anticancer agent, 1MG
MW 393.6 Da, Purity >93%. Apoptotic and anticancer agent. Selectively induces p53-independant apoptosis in cancer cells. Induces G2/M cell cycle arrest and shows antiproliferative effects. Shows antimalarial and antibactieral effects in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GR 127935 hydrochloride, 5-HT1B/1D receptor antagonist, 10MG
MW 534.06 g/mol, Purity >97%. Potent and selective 5-HT₁B/₁D receptor antagonist (pKi = 8.5 for both 5-HT₁D in rat and 5-HT₁D in guinea pig). 100-fold selectivity over 5-HT₁A, 5-HT₁E, and 5-HT₂C. Displays centrally mediated effects upon systemic administration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam L-threo-PDMP, 10MG
MW 427.03 g/mol, Purity >98%. Enantiomer of D-threo-PDMP (Asc 4052). Activates glycosyltransferases for ganglioside biosynthesis. Antineurodegenerative properties. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AR 231453, GPR119 agonist, 25MG
MW 505.5 Da, Purity >99%. Potent, selective G-protein coupled receptor 119 (GPR119) agonist (EC₅₀ = 0.68 nM). Enhances glucose-induced insulin release. Antidiabetic activity. Orally active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Radicicol, Heat shock protein (HSP) 90 inhibitor, 1MG
MW 364.8 Da, Purity >99%. Heat shock protein 90 inhibitor and antifungal antibiotic. Binds to the N-terminal ATP/ADP-binding domain suppressing cell transformation induced by src, ras and mos. Induces cell cycle arrest at G₁-S phase. Shows antiangiogenic effects in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Amylin (human), Endogenous peptide, 1MG
MW 3903.3 Da, Purity >95%. Amylin (human), Endogenous peptide. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 216763, GSK3 inhibitor, 10MG
MW 371.2 Da, Purity >98%. Potent and selective GSK3 inhibitor (Ki= 9 nM for GSK-3α). Has little activity against 24 other protein kinases (IC₅₀ > 10 μM). Stimulates glycogen synthesis, gene transcription and is cardio- and neuroprotective.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 216641 hydrochloride, h5-HT1B antagonist, 10MG
MW 523.03 g/mol, Purity >98%. Selective h5-HT₁B receptor antagonist. 25-fold selectivity over h5-HT₁D. Little or no affinity for a range of other receptor subtypes.
The product is subject to the following: Abcam Restricted Use Statement
Abcam EMD 386088 hydrochloride, 5-HT6 agonist, 10MG
MW 283.2 Da, Purity >98%. Potent 5-HT6 agonist (IC50 = 7.4 nM in 3H-LSD binding and EC50 = 1.0 nM in a functional cAMP assay). Selective over other 5-HT receptors (IC50 values are 110 (5-HT1D), 180 (5-HT1B), 240 (5-HT2A), 450 (5-HT2C), 620 (5-HT4), 660 (5-HT1A ) and 3000 nM (5-HT7)). Shows moderate affinity at 5-HT3 receptors (IC50 = 34 nM). Impairs memory *in vivo*.
The product is subject to the following: Abcam Restricted Use Statement